In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Ltd.

www.lupin.com

Latest From Lupin Ltd.

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers

Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.

Deals Cancer

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.

Japan Deals

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.

Japan Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register